Incregen Therapeutics

Incregen is raising $3M to complete FDA requirements to enable the launch of (Phase 1) human trials, paving the way for $30M Series A. With a seasoned team & de-risked operational plan, this is a compelling opportunity to enter the rapidly growing obesity market with strong potential for near-term exit.